Arrowhead Research | ARWR - Net Income

Stock Price
73.91
Daily Change
-0.49 -0.66%
Monthly
21.62%
Yearly
457.81%
Q2 Forecast
72.33

Arrowhead Research reported $30.81M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Agios Pharmaceuticals USD -108.04M 4.61M Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
Ligand Pharmaceuticals USD 117.27M 112.43M Sep/2025
Merck USD 2.96B 2.82B Dec/2025
Moderna USD -200M 625M Sep/2025
Nektar Therapeutics USD -36.08M 978K Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
TG Therapeutics USD 23.04M 367.86M Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025
Xencor USD -6.65M 626K Dec/2025